# Roche

**Type:** Funders  
**Canonical URL:** https://scholariq.org/funders/roche/

## Facts

| Field | Value |
| --- | --- |
| Country | CH |
| Description | Swiss healthcare company |
| OpenAlex ID | https://openalex.org/F4320307779 |
| ROR ID | https://ror.org/00by1q217 |
| Works | 7,598 |

## Funder papers

- [Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer](https://scholariq.org/papers/niraparib-in-patients-with-newly-diagnosed-advanced-ovarian-cancer/)
- [Safety and Efficacy of Eplerenone in Patients at High Risk for Hyperkalemia and/or Worsening Renal Function](https://scholariq.org/papers/safety-and-efficacy-of-eplerenone-in-patients-at-high-risk-for-hyperkalemia-and/)
- [Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study](https://scholariq.org/papers/durvalumab-in-combination-with-olaparib-in-patients-with-relapsed-sclc-results/)
- [A Brief Report of Transformation From NSCLC to SCLC: Molecular and Therapeutic Characteristics](https://scholariq.org/papers/a-brief-report-of-transformation-from-nsclc-to-sclc-molecular-and-therapeutic/)
- [Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors](https://scholariq.org/papers/genome-wide-profiling-of-non-smoking-related-lung-cancer-cells-reveals-common/)
- [High Prevalence of Somatic Oncogenic Driver Alterations in Patients With NSCLC and Li-Fraumeni Syndrome](https://scholariq.org/papers/high-prevalence-of-somatic-oncogenic-driver-alterations-in-patients-with-nsclc/)
- [Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial](https://scholariq.org/papers/analysis-of-resistance-mechanisms-to-abivertinib-a-third-generation-egfr/)
- [Combined versus Sequential Phacoemulsification and Pars Plana Vitrectomy](https://scholariq.org/papers/combined-versus-sequential-phacoemulsification-and-pars-plana-vitrectomy/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.